Type and route of estrogen administration

Climacteric

Volumn 12, Issue SUPPL. 1, 2009, Pages 86-90

  Stevenson, J C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

CORONARY HEART DISEASE; DIABETES MELLITUS; ESTROGEN; HEMOSTASIS; METABOLIC EFFECTS; ORAL; TRANSDERMAL; VASCULAR FUNCTION

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL;

ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG MECHANISM; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MENOPAUSE; METHODOLOGY; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; RISK FACTORS;

EID: 73949157264     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130903007389     Document Type: Article

References (18)

1. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915 (Pubitemid 32401667)
2. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004;124:802-8 (Pubitemid 38365786)
3. Stevenson, JC. Menopausal hormone therapy. In Wenger NK, Collins P, eds. Women & Heart Disease. London: Taylor & Francis, 2005:375-90
4. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298-304 (Pubitemid 27112660)
5. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000;49:742-7 (Pubitemid 30354581)
6. Kanaya AM, Herrington D, Vittinghoff V, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9 (Pubitemid 36232088)
7. Margolis KL, Bonds DE, Rodabough RJ, et al. Effects of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial. Diabetologia 2004;47:1175-87 (Pubitemid 39093314)
8. Rossi R, Origliani G, Modena MG. Transdermal 17β-estradiol and risk of developing type 2 diabetes in population of healthy, non-obese postmenopausal women. Diabetes Care 2004;27:645-9 (Pubitemid 38280527)
9. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and metaanalysis. Br Med J 2008;336:1227-31 (Pubitemid 351809317)
10. Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 2006;27:2046-53 (Pubitemid 44412809)
11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41 (Pubitemid 32003509)
12. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med 2001;135:1-8 (Pubitemid 32619277)
13. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-8
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-12
15. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34 (Pubitemid 36951364)
16. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002;109:1056-62 (Pubitemid 35279139)
17. Hsia J, Langer RD, Manson ME, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357-65
18. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2002-8